Immunocore (IMCR) Projected to Post Earnings on Thursday

Key Points

• Immunocore is set to release its Q2 2025 earnings on August 7th, with analysts predicting a loss of ($0.21) per share and revenue of $122.96 million.
• In the previous quarter, Immunocore reported earnings of $0.10 EPS, exceeding estimates, and achieved a 33.6% year-over-year revenue growth.
• Analyst ratings for Immunocore are largely positive, with a consensus price target of $58.89, and institutional investors currently hold 84.50% of the company's stock.

Immunocore (NASDAQ:IMCR - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $122.96 million for the quarter.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.45. The business had revenue of $125.13 million during the quarter, compared to analysts' expectations of $108.82 million. Immunocore had a negative return on equity of 5.86% and a negative net margin of 6.48%. The business's revenue was up 33.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.49) earnings per share. On average, analysts expect Immunocore to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immunocore Price Performance

Shares of IMCR stock traded down $0.07 during trading hours on Monday, reaching $32.92. The company had a trading volume of 24,248 shares, compared to its average volume of 335,936. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.31 and a current ratio of 6.36. The stock has a fifty day moving average of $34.26 and a 200-day moving average of $31.17. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of -76.56 and a beta of 0.77. Immunocore has a 12-month low of $23.15 and a 12-month high of $39.33.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Immunocore stock. Royal Bank of Canada grew its position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 45.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,011 shares of the company's stock after purchasing an additional 13,689 shares during the period. Royal Bank of Canada owned approximately 0.09% of Immunocore worth $1,306,000 as of its most recent SEC filing. 84.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IMCR has been the subject of a number of analyst reports. Needham & Company LLC restated a "buy" rating and issued a $71.00 price target on shares of Immunocore in a research report on Thursday, April 10th. Mizuho dropped their price target on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. Oppenheimer upped their price target on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. HC Wainwright restated a "buy" rating and issued a $100.00 price target on shares of Immunocore in a research report on Monday, June 2nd. Finally, Wall Street Zen upgraded Immunocore from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $58.89.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.